ĐÁNH GIÁ KẾT QUẢ BƯỚC ĐẦU PHƯƠNG PHÁP NÚT MẠCH HÓA CHẤT SIÊU CHỌN LỌC TRONG ĐIỀU TRỊ UNG THƯ BIỂU MÔ TẾ BÀO GAN TẠI BỆNH VIỆN K

Abstract

Objectives: The aim of this study was to evaluate the Short-term effects of ultraselective conventional transarterial chemoembolization intervention in treatment of hepatocellular carcinoma at National Cancer Hospital- Tan Trieu, from September 2021 to June 2022. Subjects   and   research   methods: Uncontrolled clinical trials study on 50 patients with confirmed diagnosis of hepatocellular carcinoma who received ultra-selective chemotherapy embolization. Results: Average number of intervention times of study subjects: 1.44 ± 0.58 times, most of them only need to intervene once 60.0%. AFP levels and tumor size at the time of follow-up after 1 month and 3 months were significantly reduced (p < 0.05 and p < 0.01). Tumor response according to mRECIST criteria: After intervention 1 month and 3 months, response rate was 84%, disease progression PD was 4.0%. Key factors related to tumor response rate according to mRECIST: AFP concentration, tumor size and portal vein visualization before intervention (p < 0.05). Post-embolization syndrome (PES): mild adominal pain 54%, no pain 46.0%. Other symptoms: fatigue 48.0%; fever 38.0%, vomiting 12.0%. There were no cases of death or complications on organs during and immediately after the intervention process. Conclusion: The ultraselective conventional transarterial chemoembolization technique is safe, has few complications, and is highly effective in the treatment of hepatocellular carcinoma.